The U.S. Food and Drug Administration (FDA) has broadened its approval for Johnson & Johnson's nasal spray, Spravato esketamine, allowing its use as a monotherapy for severe depression ...

The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...

Mental health providers in Central Illinois offering ketamine say it has changed patients' lives for the better. Still, only ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

As we honor Counseling Awareness Month,�Relief Mental Health recognizes the critical role that therapy plays in helping individuals navigate mental health challenges and build a life worth living.

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

AptarGroup is poised for growth in its Pharma and Closure segments, but challenges are expected in the Beauty segment. See ...

Greenbrook treatment centers also offer SPRAVATO ® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in ...

Demand for psychedelics-assisted psychotherapy is increasing in Switzerland, but patients still have to wait up to a year.

The FDA has expanded the approval of Valtoco (diazepam nasal spray) to include treatment of seizure clusters in patients aged 2 to 5 years.